JY
BLRX

Jeff Yass’s BioLineRX BLRX Stock Holding History

Jeff Yass’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Buy
39,000
+28,800
+282% +$83.5K ﹤0.01% 12366
2026
Q1 		$23.6K Buy
+10,200
New +$28.6K ﹤0.01% 12824
2024
Q1 		– Sell
-2,000
Closed -$126K – 12194
2023
Q4 		$126K Buy
+2,000
New +$124K ﹤0.01% 11138

Other funds holding BLRX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Jeff Yass's BLRX Position: Q2 2026 in Review

Jeff Yass opened a new position in BioLineRX (BLRX) in Q2 2026: 30,911 shares worth $95.8K. The stake represents ﹤0.01% of the portfolio and ranks #12527 among its holdings. This is a return to the name: Jeff Yass previously reported a position in BLRX as recently as Q2 2025.

Jeff Yass first reported a position in BLRX in Q1 2016 and has held it in 19 quarters since. The position peaked at $1.39M in Q1 2017. 14 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • Jeff Yass held 30,911 shares of BioLineRX worth $95.8K as of Q2 2026.
  • BioLineRX was a new Jeff Yass position in Q2 2026.
  • BioLineRX made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12527 holding.
  • Jeff Yass first reported a position in BioLineRX in Q1 2016 and has held it in 19 quarters since.
  • Jeff Yass's BioLineRX position peaked at $1.39M in Q1 2017.
  • 14 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.